跳至主要内容
临床试验/NL-OMON52506
NL-OMON52506已完成不适用

The contribution of genetic predisposition to pediatric cancer: a study integrating extensive phenotyping and state of the art genotyping. - PrediCT - Predispostion to Childhood Tumors

Prinses Máxima Centrum voor Kinderoncologie0 个研究点目标入组 843 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
843

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
0 至 64(—)

入选标准

  • Inclusion criteria for the main study PrediCT:
  • - Children (age < 19 years) newly diagnosed with cancer or neoplasms at the
  • Princess Máxima Center (in a period
  • of three years)
  • - Written informed consent (by patient when aged 16 years or older, by patient
  • and parent(s) when aged 12-16
  • years, by parent(s) when younger than 12 years)
  • Additional inclusion criteria for REFLECT:
  • - Consent for participation in PrediCT
  • - Written informed consent for REFLECT. This can include:
  • Parents (of children 0-19 years)
  • Children aged 12-16 years (additional consent by their parents needed)
  • Children aged 16-19 years.
  • Additional inclusion criteria for the Hemato add-on study:
  • - Consent for participation in PrediCT
  • - Children (age < 19 years) diagnosed with hematological malignancies
  • (including myelodysplastic syndromes) at the Princess Máxima Center
  • - Written informed consent for the Hemato add-on study (by patient when aged 16
  • years or older, by patient and parent(s) when aged 12-16 years, by parent(s)
  • when younger than 12 years).

排除标准

  • Children and/or their parents who don't want to know the results of the DNA
  • test (pediatric cancer gene panel
  • Additional exclusion criterion for REFLECT: Insufficient proficiency in Dutch.

研究者

发起方
Prinses Máxima Centrum voor Kinderoncologie

相似试验